Treatment with nanosomal paclitaxel lipid suspension < em > versus < /em > conventional paclitaxel in metastatic breast cancer patients - a multicenter, randomized, comparative, phase II/III clinical study

CONCLUSION: NPLS demonstrated an improved tumor response rate and a favorable safety profile versus conventional paclitaxel. NPLS 80 mg/m2 QW demonstrated a significantly better response versus conventional paclitaxel 175 mg/m2 Q3W.TRIAL REGISTRATION: Clinical Trial Registry-India (CTRI), CTRI/2010/091/001344 Registered on: 18 October 2010 (https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MjEzNQ==&Enc=&userName=CTRI/2010/091/001344), CTRI/2015/07/006062 Registered on: 31 July 2015 (https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTE2Mjc=&Enc=&userName=CTRI/2015/07/006062).PMID:38680290 | PMC:PMC11047258 | DOI:10.1177/17588359241236442

Source: Adv Data - April 29, 2024 Category: Epidemiology Authors: Chiradoni Thungappa Satheesh Rakesh Taran Jitendra Kumar Singh Shanti Prakash Shrivastav Nikunj K Vithalani Kalyan Kusum Mukherjee Rajnish Vasant Nagarkar Tanveer Maksud Ajay Omprakash Mehta Krishnan Srinivasan Mummaneni Vikranth Satish Ramkrishna Sonawan Source Type: research